Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-29
2006-08-29
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263350, C514S263360, C514S263220
Reexamination Certificate
active
07098217
ABSTRACT:
3,7-Dihydro-purine-2,6-dione derivatives of Formula (I) are providedwherein R1, R2, R3and R4are herein defined for use as CRF receptor ligands in the treatment of disorders characterized by overexpression of corticotropin releasing factor (CRF), such as anxiety, depression, and irritable bowel syndrome.
REFERENCES:
patent: WO 95/10506 (1995-04-01), None
patent: WO 97/35846 (1997-02-01), None
patent: WO 97/35539 (1997-10-01), None
patent: WO 97/44308 (1997-11-01), None
patent: WO 98/03510 (1998-01-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/11643 (1999-03-01), None
patent: WO 99/51608 (1999-10-01), None
patent: WO 00/01675 (2000-01-01), None
patent: WO 00/11003 (2000-03-01), None
Arato, M., et al., “elevated CSF CRF in suicide victims,”Biol. Psychiatry, 1989, 25, 355-359.
Banki, C.M., et al., “CSF corticotrophin-releasing factor-like immunoreactivity in depression and schizophrenia,”Am. J. Psychiatry, 1987, 144, 873-877.
Battaglia, C.W., et al., “Characterization of corticotrophin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system,”SYNAPSE, 1987, 1, 572-581.
Berridge, C.W., et al., “Corticotropin-releasing factor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice,”Peptides, 1986, 16, 83-93.
Blalock, J.E., “A molecular basis for bidirectional communication between the immune and neuroendocrine systems,”Physiological Reviews, 1989, 69(1), 1-32.
Britton, D.R., et al., “Intraventricular corticotrophin-releasing factor enhances behavioral effects of novety,”Life Sci., 1982, 31, 363-367.
Britton, K.T., et al., “Chlordiazepoxide attenuates response suppression induced by corticotrophin-releasing factor in the conflict test,”Psychopharmacology, 1985, 86, 170-174.
Britton, K.T., et al., “Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro15-1788 in conflict test,”Psychopharmacology, 1988, 94, 306-311.
Chrousos, G.P., “The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes,”Int. J. Obesity, 2000, 24 (Suppl. 2), S50-S55.
De Souza, E.B., et al.(Eds.), Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide,CRC Press, 1990, p. 221-224.
De Souza, E.B., et al., “Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study,”J. Neurosci., 1985, 5(12), 3189-3203.
De Souza, E.B., “CRH defects in alzheimer's and other neurologic diseases,”Hosp. Practice, Sep. 15, 1988, 23, 59-71.
Dunn., A.J., et al., “Physiological and behavioral responses to corticotrophin-releasing factor administration: is CRF a mediator of anxiety or stress responses?,”Brain Research Reviews, 1990, 15, 71-100.
France, R.D., et al., “CSF corticotrophin-releasing factor-like immunoactivity in chronic pain patients with and without major depression,”Biol. Psychiatry, 1988, 28, 86-88.
Gilligan, P.J., et al., “Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents,”J. Medicinal Chem., May 4, 2000, 43(9), 1641-1660.
Gold, P.W., et al., “Psychiatric implications basic and clinical studies with corticotrophin-releasing factor,”Am. J. Psychiatry, May 1984, 141(5), 619-627.
Gold, P.W., et al., “Responses to corticotrophin-releasing hormone in the hypercortisolism of depression and cushing's disease,”New Eng. J. Med., May 22, 1986, 314(21), 1129-1335.
Greene, et al., Protective Groups in Organic Synthesis,John Wiley&Sons, Inc., 1999.
Grigoriadis, D.E., et al., “Effects of chronic antidepressant and benzodiazepine treatment on corticotrophin-releasing-factor receptors in rat brain and pituitary,”Neuropsychopharmacology, 1989, 2(1), 53-60.
Holsboer, F., et al., “Acth and multisteroid responses to corticotrophin-releasing factor in depressive illness: relationship to multisteroid responses after acth stimulation and dexamethasone suppression,”Psychoneuroendocrinology, 1984, 9(2), 147-160.
Koob, G.F., “Neurobiology of addition toward the development of new therapies,”Ann. N.Y. Acad. Sci., 2000, 909, 170-185.
Koob, G.F., “Stress, corticotrophin-releasing factor, and behavior,”Persp. Behav. Med., 1985, 2, 39-52.
Lam, P.Y.S., et al., “Copper promoted aryl/saturated heterocyclic C-N bond cross-coupling with arylboronic acid and arylstannane,”Synlett., 2000, 5, 674-676.
Lewis, R.J. (Ed.), Hawley's Condensed Chemical Dictionary, 13thEd.,J. Wiley&Sons, Inc., NY, 1997.
Maillot, C., et al., “Peripheral corticotrophin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats,”Gastroenterology, 2000, 119, 1569-1579.
Mastorakos, G., et al., “Maternal hypothalamic-pituitary-adrenal axis in pregnancy and the postpartum period,”Ann. N.Y. Acad. Sci., 2000, 900, 95-106.
McCarthy, J.R., et al., “Recent advances with the CRF1receptor: design of small molecule inhibitors, receptor subtypes and clinical indications,”Curr. Pharm. Res., 1999, 5, 289-315.
Morley, J.E., “Minireview, neuropeptides: conductors of the immune orchestra,”Life Sci., 1987, 41, 527-544.
Munson, P.J., et al., “LIGAND: A versatile computerized approach for characterization of ligand-binding systems,”Anal. Biochem., 1980, 107, 220-239.
Nemeroff, C.B., et al., “Reduced corticotrophin releasing factor binding sites in the frontal cortex of suicide victims,”Arch. Gen. Psychiatry, Jun. 1988, 45, 577-579.
Nemeroff, C.B., et al., “Elevated concentrations of CSF corticotrophin-releasing factor-like immunoreactivity in depressed patients,”Science, 1984, 226, 1342-1344.
Newport, D.J., et al., Neurobiology of posttraumatic stress disorder,Curr. Opin. Neurobiology, 2000, 10, 211-218.
Owens, M.J., et al., “Corticotropin-releasing factor antagonists in affective disorders,”Expert Opin. Invest. Drugs, 1999, 8(11), 1849-1858.
Remington's Pharmaceutical Sciences, 17thEd.,Mack Publishing Company, Easton, PA., 1985.
Rivier, J., et al., “Characterization of rat hypothalamic corticotrophin-releasing factor,”Proc. Nat. Acad. Sci.(USA), Aug. 1983, 80, 4851-4855.
Sapolsky, R.M., “Hypercortisolism among socially subordinate wild baboons originates at the CNS level,”Arch. Gen. Psychiatry, 1989, 46, 1047-1051.
Swerdlow, N.R., et al., “Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide,”Psychopharmacology, 1986, 88, 147-152.
Vale, W., et al., Chemical and biological characterization of corticotrophin releasing factor,Rec. Prog. Horm. Res., 1983, 39 245-271.
Vale, W., et al., “characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotrophin and β-endorphin,”Science, 1981, 213, 1394-1397.
Webster, E., et al., “Corticotropin-releasing hormone and inflammation,”Ann. N.Y. Acad. Sci., 1998, 840, 21-32.
Bristol--Myers Squibb Company
Makujina Shah R.
Spivack Phyllis G.
Woodcock & Washburn LLP
LandOfFree
3,7-dihydro-purine-2,6-dione derivatives as CRF receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3605342